ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

DCT T Consider Reissuing RFA For Surgical Oncology

March 4, 1983

In Brief: House, Senate Differ On NCI Positions; Upton Says Viral Oncology research Will Be Continued

August 12, 1977

Roswell Park Wins High Priority Score, Full Budget Recommendation For Core Grant.

January 11, 2008

Progress Toward Year 2000 Goal Slow, But NCAB Says It’s Too Early, Only Data Up To ’87 Available

January 5, 1990

ONS The Largest And Still Growing With 13,000 Members

May 27, 1988

Interim Analysis Suggests Paclical Can Reduce Blood Levels

August 26, 2011